ATLANTA, GEORGIA--(CCNMatthews - June 5, 2006) - Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that Dr. David Stewart, MD, Professor of Medicine, Chief, Section of Lung Cancer Experimental Therapeutics, MD Anderson Cancer Center, and investigator for the study, will be presenting final data from Adherex's Phase I study of the molecularly targeted anti-cancer drug, ADH-1, at the 2006 American Society of Clinical Oncology Annual Meeting, a major international cancer conference in Atlanta, Georgia. The data will be presented today as an oral abstract presentation during the Developmental Therapeutics: Molecular Therapeutics session (Abstract No. 3016, 10:15 a.m. ET).
